ceftazidime + avibactam




DCH Auriga - Healthcare
Concise Prescribing Info
Ceftazidime 2 g, avibactam 0.5 g
In adults for complicated intra-abdominal infection, complicated UTI (including pyelonephritis), hospital-acquired pneumonia (including ventilator-associated pneumonia).
Dosage/Direction for Use
Hypersensitivity to ceftazidime, avibactam, to any of the excipients, or other cephalosporins. Severe hypersensitivity (eg, anaphylactic reaction, severe skin reaction) to other β-lactam antibiotics (eg, penicillins, monobactams or carbapenems).
Special Precautions
Hypersensitivity reactions; Clostridium difficile-associated diarrhea; in patients w/ renal impairment; nephrotoxicity; direct antiglobulin test (DAGT or Coombs test) seroconversion & potential risk of haemolytic anaemia; in patients w/ controlled Na diet. Ceftazidime may interfere w/ copper reduction methods (Benedict's, Fehling's, Clinitest) for detection of glycosuria leading to false-positive results. Ceftazidime does not interfere w/ enzyme-based tests for glycosuria. Should only be used during pregnancy only if the potential benefit outweighs the possible risk. Ceftazidime is excreted in human milk in small quantities & a decision must be made whether to discontinue breast-feeding or to discontinue/abstain from ceftazidime/avibactam therapy taking into account the benefit of breast-feeding for the child & the benefit of therapy for the woman.
Adverse Reactions
Positive Coombs direct test. Candidiasis (including vulvovag & oral candidiasis); eosinophilia, thrombocytosis, thrombocytopenia; headache, dizziness; diarrhoea, abdominal pain, nausea, vomiting; increased ALT, increased AST, increased blood alkaline phosphatase, increased γ-glutamyltransferase, increased blood lactate dehydrogenase; rash maculopapular, urticaria, pruritus; infusion site thrombosis &/or phlebitis, pyrexia.
Drug Interactions
Probenecid & chloramphenicol. Concurrent treatment w/ high doses of cephalosporins & nephrotoxic medicinal products eg, aminoglycosides or potent diuretics (eg, furosemide) may adversely affect renal function.
MIMS Class
ATC Classification
J01DD52 - ceftazidime and beta-lactamase inhibitor ; Belongs to the class of third-generation cephalosporins. Used in the systemic treatment of infections.
Zavicefta powd for concentrate for soln for infusion
10 × 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in